Samantha Dugard
Pronouns:
Research Mentor(s): Peter Scott
Co-Presenter:
Research Mentor School/College/Department: Nuclear Medicine/Radiology / Medicine
Presentation Date: April 20
Presentation Type: Oral5
Session: Session 6 – 4:40pm – 5:30 pm
Room: Breakout room 2
Authors:
Presenter: 6
Abstract
Cholesterol is utilized by the body in varying ways and plays a role in many different diseases such as adrenal disorders and cancer. For this reason, novel approaches to controlling cholesterol in the body is a great avenue for the treatment of these diseases. The small molecule ATR-101 was originally developed as a SOAT (also known as ACAT) inhibitor to treat atherosclerosis, but it was found to cause systolic free cholesterol toxicity at therapeutic dosing levels and was abandoned. Due to its SOAT1 specificity it was hypothesized that ATR-101 may do well as a radiotracer for imaging of adrenal disorders due to the one-time low dosage required for PET imaging (Hill, et al., 2020). ATR-101 has previously been synthesized in this lab by Dr. James Hill as a Carbon-11 radiotracer. The goal of our current project is to build on this past work in order to streamline the production of this molecule for reliable, repeatable clinical production. For this to happen a reliable stock of standard and precursor must be prepared and is where this current project is focusing. Thus far organic synthesis of ATR-101 is underway and a few radiosynthesis reactions have taken place with the product Dr. Hill previously produced.
Engineering, Interdisciplinary, Natural/Life Sciences
